MindBio Therapeutics publishes sleep research in Translational Psychiatry, demonstrating improved sleep quality with its psychedelic drug MB22001.
MindBio Therapeutics Corp. announces its scientist's sleep research published in prestigious Nature portfolio journal Translational Psychiatry. The company's novel treatment protocol using MB22001, a psychedelic drug, leads to longer sleep and improved quality of sleep after microdosing. MindBio's goal is to commercialize MB22001 as an affordable, accessible treatment for depressive disorders.
April 23, 2024
3 Articles